{"protocolSection": {"identificationModule": {"nctId": "NCT01760447", "nctIdAliases": ["NCT01472367"], "orgStudyIdInfo": {"id": "0431A-289"}, "secondaryIdInfos": [{"id": "2012-004035-23", "type": "EUDRACT_NUMBER"}, {"id": "2011-002529-23", "type": "EUDRACT_NUMBER"}, {"id": "2014-003583-20", "type": "EUDRACT_NUMBER"}, {"id": "MK-0431A-170", "type": "OTHER", "domain": "Merck Protocol Number"}, {"id": "MK-0431A-289", "type": "OTHER", "domain": "Merck Protocol Number"}, {"id": "CTRI/2012/09/003025", "type": "REGISTRY", "domain": "CTRI"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)", "officialTitle": "A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin)"}, "statusModule": {"statusVerifiedDate": "2022-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-12-07", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-09-17", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-09-17", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-01-02", "studyFirstSubmitQcDate": "2013-01-02", "studyFirstPostDateStruct": {"date": "2013-01-04", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2020-09-11", "resultsFirstSubmitQcDate": "2020-09-11", "resultsFirstPostDateStruct": {"date": "2020-10-05", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-09-09", "lastUpdatePostDateStruct": {"date": "2022-09-23", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this study is to assess the effect of the addition of sitagliptin (administered as MK-0431A or MK-0431A XR) relative to the addition of placebo on glycated hemoglobin (A1C), and the safety and tolerability of the addition of sitagliptin, in pediatric participants (ages 10-17 years) with type 2 diabetes mellitus with inadequate glycemic control on metformin therapy (alone or in combination with insulin). The primary hypothesis is that the addition of sitagliptin reduces glycated hemoglobin (A1C) more than the addition of placebo after 20 weeks of treatment."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "Participants enrolled in protocol MK-0431A-170 were randomized between the arms \"Sitagliptin/Metformin\" and \"Metformin.\" Participants enrolled in protocol MK-0431A-289 were randomized between the arms \"Sitagliptin/Metformin XR\" and \"Metformin XR.\"", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "maskingDescription": "Participants enrolled in protocol MK-0431A-170 were aware that they would receive either sitagliptin and metformin, or metformin. Participants in protocol MK-0431A-289 were aware that they would receive either sitagliptin and metformin XR, or metformin XR.", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 223, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sitagliptin/Metformin", "type": "EXPERIMENTAL", "description": "Participants received one tablet of sitagliptin/metformin and one tablet of metformin-placebo, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170.", "interventionNames": ["Drug: Sitagliptin plus metformin", "Drug: Placebo to metformin", "Drug: Insulin"]}, {"label": "Metformin", "type": "PLACEBO_COMPARATOR", "description": "Participants received one tablet of metformin and one tablet of placebo to sitagliptin/metformin, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170.", "interventionNames": ["Drug: Metformin", "Drug: Placebo to sitagliptin plus metformin", "Drug: Insulin"]}, {"label": "Sitagliptin/Metformin XR", "type": "EXPERIMENTAL", "description": "Participants received two tablets of sitagliptin/metformin XR and two tablets of metformin XR placebo, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289.", "interventionNames": ["Drug: Sitagliptin plus metformin XR", "Drug: Placebo to metformin XR", "Drug: Insulin"]}, {"label": "Metformin XR", "type": "PLACEBO_COMPARATOR", "description": "Participants received two tablets of metformin XR and two tablets of placebo to sitagliptin/metformin XR, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289.", "interventionNames": ["Drug: Insulin", "Drug: Placebo to sitagliptin plus metformin XR", "Drug: Metformin XR"]}], "interventions": [{"type": "DRUG", "name": "Sitagliptin plus metformin", "description": "Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal, to provide a total daily dose of 100 mg of sitagliptin and 1000 mg, 1700 mg or 2000 mg of metformin. Dosage of metformin was based on each participant's daily metformin dose prior to enrollment.", "armGroupLabels": ["Sitagliptin/Metformin"], "otherNames": ["MK-0431A"]}, {"type": "DRUG", "name": "Placebo to metformin", "description": "Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal. Each tablet contained placebo to metformin.", "armGroupLabels": ["Sitagliptin/Metformin"]}, {"type": "DRUG", "name": "Metformin", "description": "Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal, to provide a total daily dose of 1000 mg, 1700 mg or 2000 mg of metformin. Dosage was based on each participant's daily metformin dose prior to enrollment.", "armGroupLabels": ["Metformin"]}, {"type": "DRUG", "name": "Placebo to sitagliptin plus metformin", "description": "Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal. Each tablet contained placebo to sitagliptin plus metformin.", "armGroupLabels": ["Metformin"], "otherNames": ["Placebo to MK-0431A"]}, {"type": "DRUG", "name": "Sitagliptin plus metformin XR", "description": "Participants received 2 tablets daily, both taken together with a meal, to provide a total daily dose of 100 mg of sitagliptin and 1000 mg, 1500 mg or 2000 mg of metformin. Dosage of metformin XR was based on each participant's daily metformin dose prior to enrollment.", "armGroupLabels": ["Sitagliptin/Metformin XR"], "otherNames": ["MK-0431A XR"]}, {"type": "DRUG", "name": "Placebo to metformin XR", "description": "Participants received 2 tablets daily, both taken together with a meal. Each tablet contained placebo to metformin XR.", "armGroupLabels": ["Sitagliptin/Metformin XR"]}, {"type": "DRUG", "name": "Insulin", "description": "Participants who met protocol-specific glycemic rescue criteria received insulin as glycemic rescue therapy; participants on background insulin had their insulin dose increased for glycemic rescue. During Weeks 20-54, for participants who were not on background insulin or rescued with insulin during Weeks 0-20 in the \"Sitagliptin/Metformin\" and \"Metformin\" arms (protocol MK-0431A-170), and during Weeks 0-54 for participants not on background insulin in the \"Sitagliptin/Metformin XR\" and \"Metformin XR\" arms (protocol MK-0431A-289), the type of insulin for glycemic rescue was specified to be insulin glargine.", "armGroupLabels": ["Metformin", "Metformin XR", "Sitagliptin/Metformin", "Sitagliptin/Metformin XR"]}, {"type": "DRUG", "name": "Placebo to sitagliptin plus metformin XR", "description": "Participants received 2 tablets daily, both taken together with a meal. Each tablet contained placebo to sitagliptin plus metformin XR.", "armGroupLabels": ["Metformin XR"], "otherNames": ["Placebo to MK-0431A XR"]}, {"type": "DRUG", "name": "Metformin XR", "description": "Participants received 2 tablets daily, both taken together with a meal, to provide a total daily dose of 1000 mg, 1500 mg or 2000 mg of metformin XR. Dosage was based on each participant's daily metformin dose prior to enrollment.", "armGroupLabels": ["Metformin XR"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in A1C at Week 20", "description": "Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Mean change from baseline at Week 20 was estimated from a longitudinal data analysis model.", "timeFrame": "Baseline and Week 20"}, {"measure": "Number of Participants Who Experienced \u22651 Adverse Event During Weeks 0-20", "description": "The number of participants experiencing \u22651 adverse event during Weeks 0-20 was reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.", "timeFrame": "Up to Week 20"}, {"measure": "Number of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event During Weeks 0-20", "description": "The number of participants who discontinued from study drug due to an adverse event during Weeks 0-20 was reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.", "timeFrame": "Up to Week 20"}, {"measure": "Number of Participants Who Experienced \u22651 Adverse Event During Weeks 0-56", "description": "The number of participants experiencing \u22651 adverse event during Weeks 0-56 were reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.", "timeFrame": "Up to approximately Week 56"}, {"measure": "Number of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event During Weeks 0-54", "description": "The number of participants who discontinued from study drug due to an adverse event during Weeks 0-54 was reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.", "timeFrame": "Up to Week 54"}], "secondaryOutcomes": [{"measure": "Change From Baseline in A1C at Week 54", "description": "A1C is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Mean change from baseline at Week 54 was estimated from a longitudinal data analysis model.", "timeFrame": "Baseline and Week 54"}, {"measure": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 20", "description": "Blood glucose was measured on a fasting basis. Mean change from baseline at Week 20 was estimated from a longitudinal data analysis model.", "timeFrame": "Baseline and Week 20"}, {"measure": "Change From Baseline in FPG at Week 54", "description": "Blood glucose was measured on a fasting basis. Mean change from baseline at Week 54 was estimated from a longitudinal data analysis model.", "timeFrame": "Baseline and Week 54"}, {"measure": "Percentage of Participants With A1C at Goal (<7.0%) at Week 20", "description": "Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Percentage of participants with A1C at goal (\\<7.0%) at Week 20 was presented.", "timeFrame": "Week 20"}, {"measure": "Percentage of Participants With A1C at Goal (<6.5%) at Week 20", "description": "Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Percentage of participants with A1C at goal (\\<6.5%) at Week 20 was presented.", "timeFrame": "Week 20"}, {"measure": "Percentage of Participants With A1C at Goal (<7.0%) at Week 54", "description": "Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Percentage of participants with A1C at goal (\\<7.0%) at Week 54 was presented.", "timeFrame": "Week 54"}, {"measure": "Percentage of Participants With A1C at Goal (<6.5%) at Week 54", "description": "Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Percentage of participants with A1C at goal (\\<6.5%) at Week 54 was presented.", "timeFrame": "Week 54"}, {"measure": "Percentage of Participants Initiating Glycemic Rescue Therapy by Week 20", "description": "Percentage of participants who initiated glycemic rescue therapy prior to Week 20 was reported.", "timeFrame": "Up to Week 20"}, {"measure": "Percentage of Participants Initiating Insulin Glargine During Weeks 20-54", "description": "Percentage of participants who initiated insulin glargine therapy from Weeks 20 through 54 was reported.", "timeFrame": "Week 20 up to Week 54"}], "otherOutcomes": [{"measure": "Baseline A1C", "description": "Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.", "timeFrame": "Baseline"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* For MK-0431A-170 base study and MK-0431A-289:\n\n  * Has type 2 diabetes mellitus (T2DM)\n  * Is on metformin monotherapy (\u22651500 mg/day) for \u226512 weeks with glycated hemoglobin (A1C) \u22656.5% and \u226410.0% OR is on stable doses of metformin (\u22651500 mg/day) and insulin for \u226512 weeks with an A1C \u22657.0% and \u226410%. NOTE: Participants on a daily dose of metformin greater than or equal to 1000 mg/day, but less than 1500 mg/day may be eligible if there is documentation that higher doses are not tolerated.\n  * Participant and a family member or adult closely involved in the daily activities will participate in the participant's treatment and study protocol (i.e., available for telephone calls, study visits and administration of study medication as needed).\n  * Male, or female who is unlikely to conceive (non-sterilized, and is not sexually active or agrees to abstain from heterosexual activity or agrees to use an adequate method of contraception) during the study and for 14 days after the last dose of study drug\n* For MK-0431A-170 extension protocol:\n\n  * Has completed the P170 base study\n  * Participant and a family member or adult closely involved in the daily activities will participate in the participant's treatment and study protocol (i.e., available for telephone calls, study visits and administration of study medication as needed).\n  * Male, or female who is unlikely to conceive (non-sterilized, and is not sexually active or agrees to abstain from heterosexual activity or agrees to use an adequate method of contraception) during the study and for 14 days after the last dose of study drug\n\nExclusion Criteria:\n\n* For MK-0431A-170 base study and MK-0431A-289:\n\n  * Has type 1 diabetes mellitus\n  * Has monogenic diabetes or secondary diabetes\n  * Has symptomatic hyperglycemia and/or moderate to large ketonuria and/or positive test for ketonemia, requiring immediate initiation of another antihyperglycemic agent\n  * Has previously taken a dipeptidyl peptidase IV (DPP-4) inhibitor (such as sitagliptin, vildagliptin, alogliptin, saxagliptin, or linagliptin) or glucagon-like peptide-1 (GLP-1) receptor agonist (such as exenatide or liraglutide)\n  * Is on or likely to require treatment for \u22652 consecutive weeks or repeated courses of corticosteroids (inhaled, nasal and topical corticosteroids are permitted)\n  * Has undergone a surgical procedure within 4 weeks of study participation or has planned major surgery during the study\n  * History of congenital heart disease or cardiovascular disease other than hypertension\n  * History of active liver disease (other than non-alcoholic steatosis), including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic gallbladder disease\n  * Active neuropathy (such as nephrotic syndrome or glomerulonephritis)\n  * Chronic myopathy, mitochondrial disorder or a progressive neurological or neuromuscular disorder\n  * Human immunodeficiency virus (HIV)\n  * Hematological disorder (such as aplastic anemia, thrombocytopenia, myeloproliferative or myelodysplastic syndromes)\n  * Is currently being treated for hyperthyroidism or is on thyroid hormone therapy and has not been on a stable dose for at least 6 weeks\n  * History of malignancy for \u22645 years prior to study participation, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer\n  * History of idiopathic acute pancreatitis or chronic pancreatitis\n  * History of recreational or illicit drug use, or of alcohol abuse or dependence (within the past year)\n  * Has donated blood products or has had phlebotomy of \\>10% of estimated total blood volume within 8 weeks of study participation, or intends to donate blood products or receive blood products within the projected duration of the study\n  * Is pregnant or breast-feeding, or is expecting to conceive or donate eggs during the study, including 14 days following the last dose of study drug\n* For MK-0431A-170 extension protocol:\n\n  * Participant meets a study medication discontinuation criterion at the last visit of the MK-0431A-170 base study (Week 20)\n  * Has taken the last dose of study medication for the MK-0431A-170 base study more than 14 days prior to Extension Visit 1\n  * Has initiated another oral antihyperglycemic agent\n  * Participant does not agree to refrain from participating in any other double-blind interventional study while participating in the P170 extension study", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "10 Years", "maximumAge": "17 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Director", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "34779103", "type": "DERIVED", "citation": "Jalaludin MY, Deeb A, Zeitler P, Garcia R, Newfield RS, Samoilova Y, Rosario CA, Shehadeh N, Saha CK, Zhang Y, Zilli M, Scherer LW, Lam RLH, Golm GT, Engel SS, Kaufman KD, Shankar RR. Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulin. Pediatr Diabetes. 2022 Mar;23(2):183-193. doi: 10.1111/pedi.13282. Epub 2021 Dec 20."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf", "url": "http://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The Pre-Assignment Period included a one-week single-blind placebo run-in prior to randomization during which participants received metformin with sitagliptin/metformin placebo or metformin XR with sitagliptin/metformin XR placebo each day.", "recruitmentDetails": "The study recruited participants in clinics/clinical offices in 28 countries.\n\nOne participant who was randomized to the arm \"Sitagliptin/Metformin\" withdrew prior to treatment, then was re-randomized into the study. Only the second randomization is counted for Participant Flow and All-Cause Mortality, so this participant is not counted twice.", "groups": [{"id": "FG000", "title": "Sitagliptin/Metformin", "description": "Participants received one tablet of sitagliptin/metformin and one tablet of metformin-placebo, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170."}, {"id": "FG001", "title": "Metformin", "description": "Participants received one tablet of metformin and one tablet of placebo to sitagliptin/metformin, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170."}, {"id": "FG002", "title": "Sitagliptin/Metformin XR", "description": "Participants received two tablets of sitagliptin/metformin XR and two tablets of metformin XR placebo, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289."}, {"id": "FG003", "title": "Metformin XR", "description": "Participants received two tablets of metformin XR and two tablets of placebo to sitagliptin/metformin XR, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289."}], "periods": [{"title": "Weeks 0-20", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "The first randomization for the participant who withdrew and re-randomized is not counted in the 62.", "numSubjects": "62"}, {"groupId": "FG001", "numSubjects": "62"}, {"groupId": "FG002", "numSubjects": "47"}, {"groupId": "FG003", "numSubjects": "51"}]}, {"type": "Treated", "achievements": [{"groupId": "FG000", "numSubjects": "62"}, {"groupId": "FG001", "numSubjects": "62"}, {"groupId": "FG002", "numSubjects": "45"}, {"groupId": "FG003", "numSubjects": "51"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "59"}, {"groupId": "FG001", "numSubjects": "62"}, {"groupId": "FG002", "numSubjects": "42"}, {"groupId": "FG003", "numSubjects": "47"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "4"}]}], "dropWithdraws": [{"type": "Consent withdrawn by Parent/Guardian", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "3"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Randomized but not treated", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Weeks 20-54", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "MK-0431A-170 added Weeks 20-54 via amendment, but not all participants were eligible for this period", "numSubjects": "28"}, {"groupId": "FG001", "comment": "MK-0431A-170 added Weeks 20-54 via amendment, but not all participants were eligible for this period", "numSubjects": "30"}, {"groupId": "FG002", "numSubjects": "42"}, {"groupId": "FG003", "numSubjects": "47"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "25"}, {"groupId": "FG001", "numSubjects": "28"}, {"groupId": "FG002", "numSubjects": "39"}, {"groupId": "FG003", "numSubjects": "43"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "4"}]}], "dropWithdraws": [{"type": "Consent withdrawn by Parent/Guardian", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "The baseline characteristics data are presented for all treated participants.", "groups": [{"id": "BG000", "title": "Sitagliptin/Metformin", "description": "Participants received one tablet of sitagliptin/metformin and one tablet of metformin-placebo, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170."}, {"id": "BG001", "title": "Metformin", "description": "Participants received one tablet of metformin and one tablet of placebo to sitagliptin/metformin, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170."}, {"id": "BG002", "title": "Sitagliptin/Metformin XR", "description": "Participants received two tablets of sitagliptin/metformin XR and two tablets of metformin XR placebo, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289."}, {"id": "BG003", "title": "Metformin XR", "description": "Participants received two tablets of metformin XR and two tablets of placebo to sitagliptin/metformin XR, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289."}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "62"}, {"groupId": "BG001", "value": "62"}, {"groupId": "BG002", "value": "45"}, {"groupId": "BG003", "value": "51"}, {"groupId": "BG004", "value": "220"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "14.4", "spread": "2.2"}, {"groupId": "BG001", "value": "13.9", "spread": "1.8"}, {"groupId": "BG002", "value": "14.8", "spread": "1.9"}, {"groupId": "BG003", "value": "14.9", "spread": "1.6"}, {"groupId": "BG004", "value": "14.4", "spread": "1.9"}]}]}]}, {"title": "Age, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "In utero", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Preterm newborn infants (gestational age < 37 wks)", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Newborns (0-27 days)", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Infants and toddlers (28 days-23 months)", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Children (2-11 years)", "measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "21"}]}, {"title": "Adolescents (12-17 years)", "measurements": [{"groupId": "BG000", "value": "52"}, {"groupId": "BG001", "value": "55"}, {"groupId": "BG002", "value": "42"}, {"groupId": "BG003", "value": "50"}, {"groupId": "BG004", "value": "199"}]}, {"title": "Adults (18-64 years)", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "From 65-84 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "85 years and over", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "41"}, {"groupId": "BG001", "value": "40"}, {"groupId": "BG002", "value": "32"}, {"groupId": "BG003", "value": "32"}, {"groupId": "BG004", "value": "145"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "13"}, {"groupId": "BG003", "value": "19"}, {"groupId": "BG004", "value": "75"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "11"}, {"groupId": "BG003", "value": "20"}, {"groupId": "BG004", "value": "77"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "35"}, {"groupId": "BG001", "value": "36"}, {"groupId": "BG002", "value": "29"}, {"groupId": "BG003", "value": "28"}, {"groupId": "BG004", "value": "128"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "3"}, {"groupId": "BG004", "value": "15"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "9"}, {"groupId": "BG004", "value": "13"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "15"}, {"groupId": "BG003", "value": "6"}, {"groupId": "BG004", "value": "64"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "2"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "4"}, {"groupId": "BG004", "value": "10"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "22"}, {"groupId": "BG003", "value": "27"}, {"groupId": "BG004", "value": "96"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "5"}, {"groupId": "BG004", "value": "35"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}]}]}, {"title": "Glycated Hemoglobin (A1C)", "description": "Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percentage", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.02", "spread": "1.22"}, {"groupId": "BG001", "value": "8.13", "spread": "1.08"}, {"groupId": "BG002", "value": "7.87", "spread": "0.94"}, {"groupId": "BG003", "value": "7.97", "spread": "1.05"}, {"groupId": "BG004", "value": "8.0", "spread": "1.1"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in A1C at Week 20", "description": "Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Mean change from baseline at Week 20 was estimated from a longitudinal data analysis model.", "populationDescription": "The analysis population includes all randomized participants who received \u22651 dose of study medication and who had at least 1 measurement of A1C. As defined in the protocols, these analyses were conducted in participants pooled from protocols MK-0431A-170 and MK-0431A-289, pooled according to receipt of experimental drug or placebo comparator.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage of glycated hemoglobin", "timeFrame": "Baseline and Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the experimental-drug groups \"Sitagliptin/Metformin\" (from protocol MK-0431A-170) and \"Sitagliptin/Metformin XR\" (from protocol MK-0431A-289)."}, {"id": "OG001", "title": "Metformin and Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the placebo groups \"Metformin\" (from protocol MK-0431A-170) and \"Metformin XR\" (from protocol MK-0431A-289)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "113"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.58", "lowerLimit": "-0.94", "upperLimit": "-0.22"}, {"groupId": "OG001", "value": "-0.09", "lowerLimit": "-0.43", "upperLimit": "0.26"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The Least Squares (LS) Mean for the arm \"Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled\" is compared against that of \"Metformin and Metformin XR Pooled.\"", "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.018", "statisticalMethod": "Mixed Models Analysis", "paramType": "Least Squares Mean Difference", "paramValue": "-0.49", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.90", "ciUpperLimit": "-0.09"}]}, {"type": "PRIMARY", "title": "Number of Participants Who Experienced \u22651 Adverse Event During Weeks 0-20", "description": "The number of participants experiencing \u22651 adverse event during Weeks 0-20 was reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.", "populationDescription": "The analysis population includes all randomized participants who received \u22651 dose of study medication.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin/Metformin", "description": "Participants received one tablet of sitagliptin/metformin and one tablet of metformin-placebo, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170."}, {"id": "OG001", "title": "Metformin", "description": "Participants received one tablet of metformin and one tablet of placebo to sitagliptin/metformin, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170."}, {"id": "OG002", "title": "Sitagliptin/Metformin XR", "description": "Participants received two tablets of sitagliptin/metformin XR and two tablets of metformin XR placebo, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289."}, {"id": "OG003", "title": "Metformin XR", "description": "Participants received two tablets of metformin XR and two tablets of placebo to sitagliptin/metformin XR, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289."}, {"id": "OG004", "title": "Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the experimental-drug groups \"Sitagliptin/Metformin\" (from protocol MK-0431A-170) and \"Sitagliptin/Metformin XR\" (from protocol MK-0431A-289)."}, {"id": "OG005", "title": "Metformin and Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the placebo groups \"Metformin\" (from protocol MK-0431A-170) and \"Metformin XR\" (from protocol MK-0431A-289)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "62"}, {"groupId": "OG002", "value": "45"}, {"groupId": "OG003", "value": "51"}, {"groupId": "OG004", "value": "107"}, {"groupId": "OG005", "value": "113"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "46"}, {"groupId": "OG002", "value": "29"}, {"groupId": "OG003", "value": "30"}, {"groupId": "OG004", "value": "71"}, {"groupId": "OG005", "value": "76"}]}]}], "analyses": [{"groupIds": ["OG004", "OG005"], "groupDescription": "The percentage of participants who experienced \u22651 adverse event for the arm \"Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled\" is compared against that of \"Metformin and Metformin XR Pooled.\"", "nonInferiorityType": "OTHER", "paramType": "Difference in Percentage", "paramValue": "-1.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-13.9", "ciUpperLimit": "11.3", "estimateComment": "The Miettinen and Nurminen methodology was used to calculate the difference and 95% confidence interval."}]}, {"type": "PRIMARY", "title": "Number of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event During Weeks 0-20", "description": "The number of participants who discontinued from study drug due to an adverse event during Weeks 0-20 was reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.", "populationDescription": "The analysis population includes all randomized participants who received \u22651 dose of study medication.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin/Metformin", "description": "Participants received one tablet of sitagliptin/metformin and one tablet of metformin-placebo, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170."}, {"id": "OG001", "title": "Metformin", "description": "Participants received one tablet of metformin and one tablet of placebo to sitagliptin/metformin, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170."}, {"id": "OG002", "title": "Sitagliptin/Metformin XR", "description": "Participants received two tablets of sitagliptin/metformin XR and two tablets of metformin XR placebo, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289."}, {"id": "OG003", "title": "Metformin XR", "description": "Participants received two tablets of metformin XR and two tablets of placebo to sitagliptin/metformin XR, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289."}, {"id": "OG004", "title": "Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the experimental-drug groups \"Sitagliptin/Metformin\" (from protocol MK-0431A-170) and \"Sitagliptin/Metformin XR\" (from protocol MK-0431A-289)."}, {"id": "OG005", "title": "Metformin and Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the placebo groups \"Metformin\" (from protocol MK-0431A-170) and \"Metformin XR\" (from protocol MK-0431A-289)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "62"}, {"groupId": "OG002", "value": "45"}, {"groupId": "OG003", "value": "51"}, {"groupId": "OG004", "value": "107"}, {"groupId": "OG005", "value": "113"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "2"}, {"groupId": "OG004", "value": "3"}, {"groupId": "OG005", "value": "4"}]}]}], "analyses": [{"groupIds": ["OG004", "OG005"], "groupDescription": "The percentage of participants who discontinued study drug due to experiencing an adverse event for the arm \"Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled\" is compared against that of \"Metformin and Metformin XR Pooled.\"", "nonInferiorityType": "OTHER", "paramType": "Difference in Percentage", "paramValue": "-0.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.2", "ciUpperLimit": "5.0", "estimateComment": "The Miettinen and Nurminen methodology was used to calculate the difference and 95% confidence interval."}]}, {"type": "PRIMARY", "title": "Number of Participants Who Experienced \u22651 Adverse Event During Weeks 0-56", "description": "The number of participants experiencing \u22651 adverse event during Weeks 0-56 were reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.", "populationDescription": "The analysis population includes all randomized participants who received \u22651 dose of study medication and continued in the study beyond Week 20.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to approximately Week 56", "groups": [{"id": "OG000", "title": "Sitagliptin/Metformin", "description": "Participants received one tablet of sitagliptin/metformin and one tablet of metformin-placebo, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170."}, {"id": "OG001", "title": "Metformin", "description": "Participants received one tablet of metformin and one tablet of placebo to sitagliptin/metformin, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170."}, {"id": "OG002", "title": "Sitagliptin/Metformin XR", "description": "Participants received two tablets of sitagliptin/metformin XR and two tablets of metformin XR placebo, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289."}, {"id": "OG003", "title": "Metformin XR", "description": "Participants received two tablets of metformin XR and two tablets of placebo to sitagliptin/metformin XR, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289."}, {"id": "OG004", "title": "Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the experimental-drug groups \"Sitagliptin/Metformin\" (from protocol MK-0431A-170) and \"Sitagliptin/Metformin XR\" (from protocol MK-0431A-289)."}, {"id": "OG005", "title": "Metformin and Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the placebo groups \"Metformin\" (from protocol MK-0431A-170) and \"Metformin XR\" (from protocol MK-0431A-289)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "42"}, {"groupId": "OG003", "value": "47"}, {"groupId": "OG004", "value": "70"}, {"groupId": "OG005", "value": "77"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "27"}, {"groupId": "OG002", "value": "36"}, {"groupId": "OG003", "value": "39"}, {"groupId": "OG004", "value": "62"}, {"groupId": "OG005", "value": "66"}]}]}], "analyses": [{"groupIds": ["OG004", "OG005"], "groupDescription": "The percentage of participants who experienced \u22651 adverse event for the arm \"Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled\" is compared against that of \"Metformin and Metformin XR Pooled.\"", "nonInferiorityType": "OTHER", "paramType": "Difference in Percentage", "paramValue": "2.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.9", "ciUpperLimit": "14.4", "estimateComment": "The Miettinen and Nurminen methodology was used to calculate the difference and 95% confidence interval."}]}, {"type": "PRIMARY", "title": "Number of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event During Weeks 0-54", "description": "The number of participants who discontinued from study drug due to an adverse event during Weeks 0-54 was reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.", "populationDescription": "The analysis population includes all randomized participants who received \u22651 dose of study medication and continued in the study beyond Week 20.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin/Metformin", "description": "Participants received one tablet of sitagliptin/metformin and one tablet of metformin-placebo, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170."}, {"id": "OG001", "title": "Metformin", "description": "Participants received one tablet of metformin and one tablet of placebo to sitagliptin/metformin, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170."}, {"id": "OG002", "title": "Sitagliptin/Metformin XR", "description": "Participants received two tablets of sitagliptin/metformin XR and two tablets of metformin XR placebo, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289."}, {"id": "OG003", "title": "Metformin XR", "description": "Participants received two tablets of metformin XR and two tablets of placebo to sitagliptin/metformin XR, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289."}, {"id": "OG004", "title": "Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the experimental-drug groups \"Sitagliptin/Metformin\" (from protocol MK-0431A-170) and \"Sitagliptin/Metformin XR\" (from protocol MK-0431A-289)."}, {"id": "OG005", "title": "Metformin and Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the placebo groups \"Metformin\" (from protocol MK-0431A-170) and \"Metformin XR\" (from protocol MK-0431A-289)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "42"}, {"groupId": "OG003", "value": "47"}, {"groupId": "OG004", "value": "70"}, {"groupId": "OG005", "value": "77"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "3"}, {"groupId": "OG004", "value": "2"}, {"groupId": "OG005", "value": "4"}]}]}], "analyses": [{"groupIds": ["OG004", "OG005"], "groupDescription": "The percentage of participants who discontinued study drug due to experiencing an adverse event for the arm \"Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled\" is compared against that of \"Metformin and Metformin XR Pooled.\"", "nonInferiorityType": "OTHER", "paramType": "Difference in Percentage", "paramValue": "-2.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-10.1", "ciUpperLimit": "5.8", "estimateComment": "The Miettinen and Nurminen methodology was used to calculate the difference and 95% confidence interval."}]}, {"type": "SECONDARY", "title": "Change From Baseline in A1C at Week 54", "description": "A1C is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Mean change from baseline at Week 54 was estimated from a longitudinal data analysis model.", "populationDescription": "The analysis population includes all randomized participants who received \u22651 dose of study medication, had \u22651 measurement of A1C, and continued in the study beyond Week 20. As defined in the protocols, these analyses were conducted in participants pooled from protocols MK-0431A-170 and -289, pooled by receipt of experimental drug or placebo.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage of glycated hemoglobin", "timeFrame": "Baseline and Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the experimental-drug groups \"Sitagliptin/Metformin\" (from protocol MK-0431A-170) and \"Sitagliptin/Metformin XR\" (from protocol MK-0431A-289)."}, {"id": "OG001", "title": "Metformin and Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the placebo groups \"Metformin\" (from protocol MK-0431A-170) and \"Metformin XR\" (from protocol MK-0431A-289)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "77"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.35", "lowerLimit": "-0.48", "upperLimit": "1.19"}, {"groupId": "OG001", "value": "0.73", "lowerLimit": "-0.08", "upperLimit": "1.54"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 20", "description": "Blood glucose was measured on a fasting basis. Mean change from baseline at Week 20 was estimated from a longitudinal data analysis model.", "populationDescription": "The analysis population includes all randomized participants who received \u22651 dose of study medication, and who had at least 1 measurement of FPG. As defined in the protocols, these analyses were conducted in participants pooled from protocols MK-0431A-170 and MK-0431A-289, pooled according to receipt of experimental drug or placebo comparator.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the experimental-drug groups \"Sitagliptin/Metformin\" (from protocol MK-0431A-170) and \"Sitagliptin/Metformin XR\" (from protocol MK-0431A-289)."}, {"id": "OG001", "title": "Metformin and Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the placebo groups \"Metformin\" (from protocol MK-0431A-170) and \"Metformin XR\" (from protocol MK-0431A-289)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "113"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.5", "lowerLimit": "-16.7", "upperLimit": "11.7"}, {"groupId": "OG001", "value": "8.3", "lowerLimit": "-5.0", "upperLimit": "21.6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The Least Squares (LS) Mean for the arm \"Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled\" is compared against that of \"Metformin and Metformin XR Pooled.\"", "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.159", "statisticalMethod": "Mixed Models Analysis", "paramType": "Least Squares Mean Difference", "paramValue": "-10.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-25.9", "ciUpperLimit": "4.3"}]}, {"type": "SECONDARY", "title": "Change From Baseline in FPG at Week 54", "description": "Blood glucose was measured on a fasting basis. Mean change from baseline at Week 54 was estimated from a longitudinal data analysis model.", "populationDescription": "The analysis population includes all randomized participants who received \u22651 dose of study medication, had \u22651 measurement of FPG, and continued in the study beyond Week 20. As defined in the protocols, these analyses were conducted in participants pooled from protocols MK-0431A-170 and -289, pooled by receipt of experimental drug or placebo.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the experimental-drug groups \"Sitagliptin/Metformin\" (from protocol MK-0431A-170) and \"Sitagliptin/Metformin XR\" (from protocol MK-0431A-289)."}, {"id": "OG001", "title": "Metformin and Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the placebo groups \"Metformin\" (from protocol MK-0431A-170) and \"Metformin XR\" (from protocol MK-0431A-289)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "77"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "16.8", "lowerLimit": "-8.4", "upperLimit": "42.0"}, {"groupId": "OG001", "value": "16.9", "lowerLimit": "-7.0", "upperLimit": "40.8"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With A1C at Goal (<7.0%) at Week 20", "description": "Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Percentage of participants with A1C at goal (\\<7.0%) at Week 20 was presented.", "populationDescription": "The analysis population includes all randomized participants who received \u22651 dose of study medication. As defined in the protocols, these analyses were conducted in participants pooled from protocols MK-0431A-170 and MK-0431A-289, pooled according to receipt of experimental drug or placebo comparator.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the experimental-drug groups \"Sitagliptin/Metformin\" (from protocol MK-0431A-170) and \"Sitagliptin/Metformin XR\" (from protocol MK-0431A-289)."}, {"id": "OG001", "title": "Metformin and Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the placebo groups \"Metformin\" (from protocol MK-0431A-170) and \"Metformin XR\" (from protocol MK-0431A-289)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "113"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "43.0"}, {"groupId": "OG001", "value": "31.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The percentage of participants with A1C at the A1C goal (\\<7.0%) in the arm \"Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled\" is compared against that of \"Metformin and Metformin XR Pooled.\" For estimating the treatment difference, when the A1C result for a participant at Week 20 was not available, a multiple imputation method was used to impute whether the participant had met the goal.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.017", "statisticalMethod": "Miettinen and Nurminen", "paramType": "Difference in Percentage", "paramValue": "16.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.9", "ciUpperLimit": "28.9"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With A1C at Goal (<6.5%) at Week 20", "description": "Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Percentage of participants with A1C at goal (\\<6.5%) at Week 20 was presented.", "populationDescription": "The analysis population includes all randomized participants who received \u22651 dose of study medication. As defined in the protocols, these analyses were conducted in participants pooled from protocols MK-0431A-170 and MK-0431A-289, pooled according to receipt of experimental drug or placebo comparator.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the experimental-drug groups \"Sitagliptin/Metformin\" (from protocol MK-0431A-170) and \"Sitagliptin/Metformin XR\" (from protocol MK-0431A-289)."}, {"id": "OG001", "title": "Metformin and Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the placebo groups \"Metformin\" (from protocol MK-0431A-170) and \"Metformin XR\" (from protocol MK-0431A-289)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "113"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "29.0"}, {"groupId": "OG001", "value": "20.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The percentage of participants with A1C at the A1C goal (\\<6.5%) in the arm \"Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled\" is compared against that of \"Metformin and Metformin XR Pooled.\" For estimating the treatment difference, when the A1C result for a participant at Week 20 was not available, a multiple imputation method was used to impute whether the participant had met the goal.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.049", "statisticalMethod": "Miettinen and Nurminen", "paramType": "Difference in Percentage", "paramValue": "12.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.0", "ciUpperLimit": "24.8"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With A1C at Goal (<7.0%) at Week 54", "description": "Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Percentage of participants with A1C at goal (\\<7.0%) at Week 54 was presented.", "populationDescription": "The analysis population includes all randomized participants who received \u22651 dose of study medication and continued in the study beyond Week 20. As defined in the protocols, these analyses were conducted in participants pooled from protocols MK-0431A-170 and MK-0431A-289, pooled according to receipt of experimental drug or placebo comparator.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the experimental-drug groups \"Sitagliptin/Metformin\" (from protocol MK-0431A-170) and \"Sitagliptin/Metformin XR\" (from protocol MK-0431A-289)."}, {"id": "OG001", "title": "Metformin and Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the placebo groups \"Metformin\" (from protocol MK-0431A-170) and \"Metformin XR\" (from protocol MK-0431A-289)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "77"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "31.4"}, {"groupId": "OG001", "value": "27.3"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With A1C at Goal (<6.5%) at Week 54", "description": "Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Percentage of participants with A1C at goal (\\<6.5%) at Week 54 was presented.", "populationDescription": "The analysis population includes all randomized participants who received \u22651 dose of study medication and continued in the study beyond Week 20. As defined in the protocols, these analyses were conducted in participants pooled from protocols MK-0431A-170 and MK-0431A-289, pooled according to receipt of experimental drug or placebo comparator.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the experimental-drug groups \"Sitagliptin/Metformin\" (from protocol MK-0431A-170) and \"Sitagliptin/Metformin XR\" (from protocol MK-0431A-289)."}, {"id": "OG001", "title": "Metformin and Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the placebo groups \"Metformin\" (from protocol MK-0431A-170) and \"Metformin XR\" (from protocol MK-0431A-289)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "77"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "18.6"}, {"groupId": "OG001", "value": "19.5"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Initiating Glycemic Rescue Therapy by Week 20", "description": "Percentage of participants who initiated glycemic rescue therapy prior to Week 20 was reported.", "populationDescription": "The analysis population includes all randomized participants who received \u22651 dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to Week 20", "groups": [{"id": "OG000", "title": "Sitagliptin/Metformin", "description": "Participants received one tablet of sitagliptin/metformin and one tablet of metformin-placebo, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170."}, {"id": "OG001", "title": "Metformin", "description": "Participants received one tablet of metformin and one tablet of placebo to sitagliptin/metformin, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170."}, {"id": "OG002", "title": "Sitagliptin/Metformin XR", "description": "Participants received two tablets of sitagliptin/metformin XR and two tablets of metformin XR placebo, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289."}, {"id": "OG003", "title": "Metformin XR", "description": "Participants received two tablets of metformin XR and two tablets of placebo to sitagliptin/metformin XR, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289."}, {"id": "OG004", "title": "Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the experimental-drug groups \"Sitagliptin/Metformin\" (from protocol MK-0431A-170) and \"Sitagliptin/Metformin XR\" (from protocol MK-0431A-289)."}, {"id": "OG005", "title": "Metformin and Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the placebo groups \"Metformin\" (from protocol MK-0431A-170) and \"Metformin XR\" (from protocol MK-0431A-289)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "62"}, {"groupId": "OG002", "value": "45"}, {"groupId": "OG003", "value": "51"}, {"groupId": "OG004", "value": "107"}, {"groupId": "OG005", "value": "113"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.2"}, {"groupId": "OG001", "value": "19.4"}, {"groupId": "OG002", "value": "4.4"}, {"groupId": "OG003", "value": "13.7"}, {"groupId": "OG004", "value": "3.7"}, {"groupId": "OG005", "value": "16.8"}]}]}], "analyses": [{"groupIds": ["OG004", "OG005"], "groupDescription": "The percentage of participants initiating glycemic rescue therapy in the arm \"Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled\" is compared against that of \"Metformin and Metformin XR Pooled.\"", "nonInferiorityType": "SUPERIORITY", "pValue": "0.002", "statisticalMethod": "Log-Rank Test", "paramType": "Kaplan-Meier Difference in Percentage", "paramValue": "-13.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-21.1", "ciUpperLimit": "-5.3"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Initiating Insulin Glargine During Weeks 20-54", "description": "Percentage of participants who initiated insulin glargine therapy from Weeks 20 through 54 was reported.", "populationDescription": "The analysis population includes all randomized participants who received \u22651 dose of study medication and continued in the study beyond Week 20 without initiating glycemic rescue therapy before Week 20. As defined in the protocols, these analyses were on participants pooled from protocols MK-0431A-170 and -289, pooled by receipt of drug or placebo.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 20 up to Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the experimental-drug groups \"Sitagliptin/Metformin\" (from protocol MK-0431A-170) and \"Sitagliptin/Metformin XR\" (from protocol MK-0431A-289)."}, {"id": "OG001", "title": "Metformin and Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the placebo groups \"Metformin\" (from protocol MK-0431A-170) and \"Metformin XR\" (from protocol MK-0431A-289)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "66"}, {"groupId": "OG001", "value": "64"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "22.7"}, {"groupId": "OG001", "value": "26.6"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Baseline A1C", "description": "Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.", "populationDescription": "The analysis population includes all randomized participants who received \u22651 dose of study medication and had a baseline measurement of A1C. Baseline A1C data for non-pooled arms are listed in the Baseline Characteristics module.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of glycated hemoglobin", "timeFrame": "Baseline", "groups": [{"id": "OG000", "title": "Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the experimental-drug groups \"Sitagliptin/Metformin\" (from protocol MK-0431A-170) and \"Sitagliptin/Metformin XR\" (from protocol MK-0431A-289)."}, {"id": "OG001", "title": "Metformin and Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the placebo groups \"Metformin\" (from protocol MK-0431A-170) and \"Metformin XR\" (from protocol MK-0431A-289)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "113"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.96", "spread": "1.11"}, {"groupId": "OG001", "value": "8.06", "spread": "1.07"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 56 weeks for non-serious adverse events. Up to approximately 76 weeks for serious adverse events. Up to approximately 78 weeks for all-cause mortality.", "description": "\"Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled\" = \"Sitagliptin/Metformin\" plus \"Sitagliptin/Metformin XR.\" \"Metformin and Metformin XR Pooled\" = \"Metformin\" plus \"Metformin XR.\"\n\nNon-serious and serious adverse events are recorded for all treated participants.\n\nAll-cause mortality is recorded for all randomized participants.", "eventGroups": [{"id": "EG000", "title": "Sitagliptin/Metformin", "description": "Participants received one tablet of sitagliptin/metformin and one tablet of metformin-placebo, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170.", "deathsNumAffected": 1, "deathsNumAtRisk": 62, "seriousNumAffected": 4, "seriousNumAtRisk": 62, "otherNumAffected": 34, "otherNumAtRisk": 62}, {"id": "EG001", "title": "Metformin", "description": "Participants received one tablet of metformin and one tablet of placebo to sitagliptin/metformin, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170.", "deathsNumAffected": 0, "deathsNumAtRisk": 62, "seriousNumAffected": 3, "seriousNumAtRisk": 62, "otherNumAffected": 40, "otherNumAtRisk": 62}, {"id": "EG002", "title": "Sitagliptin/Metformin XR", "description": "Participants received two tablets of sitagliptin/metformin XR and two tablets of metformin XR placebo, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289.", "deathsNumAffected": 0, "deathsNumAtRisk": 47, "seriousNumAffected": 3, "seriousNumAtRisk": 45, "otherNumAffected": 30, "otherNumAtRisk": 45}, {"id": "EG003", "title": "Metformin XR", "description": "Participants received two tablets of metformin XR and two tablets of placebo to sitagliptin/metformin XR, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289.", "deathsNumAffected": 0, "deathsNumAtRisk": 51, "seriousNumAffected": 3, "seriousNumAtRisk": 51, "otherNumAffected": 36, "otherNumAtRisk": 51}, {"id": "EG004", "title": "Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the experimental-drug groups \"Sitagliptin/Metformin\" (from protocol MK-0431A-170) and \"Sitagliptin/Metformin XR\" (from protocol MK-0431A-289).", "deathsNumAffected": 1, "deathsNumAtRisk": 109, "seriousNumAffected": 7, "seriousNumAtRisk": 107, "otherNumAffected": 64, "otherNumAtRisk": 107}, {"id": "EG005", "title": "Metformin and Metformin XR Pooled", "description": "This reporting group contains the pooled population of treated participants from the placebo groups \"Metformin\" (from protocol MK-0431A-170) and \"Metformin XR\" (from protocol MK-0431A-289).", "deathsNumAffected": 0, "deathsNumAtRisk": 113, "seriousNumAffected": 6, "seriousNumAtRisk": 113, "otherNumAffected": 76, "otherNumAtRisk": 113}], "seriousEvents": [{"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 113}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 113}]}, {"term": "Type I hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}]}, {"term": "H1N1 influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 113}]}, {"term": "Pyelonephritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}]}, {"term": "Blood glucose increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 113}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 2, "numAffected": 2, "numAtRisk": 113}]}, {"term": "Synovial cyst", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}]}, {"term": "Epilepsy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 113}]}, {"term": "Suicide attempt", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 113}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}]}, {"term": "Death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}]}], "otherEvents": [{"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 4, "numAffected": 4, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 6, "numAffected": 6, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 8, "numAffected": 8, "numAtRisk": 113}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 4, "numAffected": 3, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 2, "numAffected": 1, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 6, "numAffected": 5, "numAtRisk": 113}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 7, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 10, "numAffected": 3, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 9, "numAffected": 8, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 14, "numAffected": 7, "numAtRisk": 113}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 2, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 6, "numAffected": 4, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 3, "numAffected": 2, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 11, "numAffected": 6, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 8, "numAffected": 7, "numAtRisk": 113}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 5, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 9, "numAffected": 8, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 5, "numAffected": 5, "numAtRisk": 113}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 5, "numAffected": 4, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 3, "numAffected": 2, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 5, "numAffected": 3, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 4, "numAffected": 3, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 10, "numAffected": 7, "numAtRisk": 113}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 7, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 7, "numAffected": 7, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 3, "numAffected": 2, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 13, "numAffected": 8, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 10, "numAffected": 9, "numAtRisk": 113}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 6, "numAffected": 5, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 2, "numAffected": 2, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 9, "numAffected": 8, "numAtRisk": 113}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 9, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 8, "numAffected": 6, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 9, "numAffected": 5, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 5, "numAffected": 3, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 20, "numAffected": 14, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 13, "numAffected": 9, "numAtRisk": 113}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 6, "numAffected": 5, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 3, "numAffected": 3, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 7, "numAffected": 6, "numAtRisk": 113}]}, {"term": "Alanine aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 3, "numAffected": 3, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 6, "numAffected": 5, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 6, "numAffected": 6, "numAtRisk": 113}]}, {"term": "Blood creatine phosphokinase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 6, "numAffected": 6, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 2, "numAffected": 2, "numAtRisk": 113}]}, {"term": "Blood glucose increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 5, "numAffected": 3, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 6, "numAffected": 5, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 5, "numAffected": 3, "numAtRisk": 113}]}, {"term": "Creatinine renal clearance increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 4, "numAffected": 4, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 113}]}, {"term": "Urine albumin/creatinine ratio increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 4, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 5, "numAffected": 4, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 2, "numAffected": 2, "numAtRisk": 113}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 6, "numAffected": 5, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 4, "numAffected": 4, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 6, "numAffected": 6, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 10, "numAffected": 9, "numAtRisk": 113}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 106, "numAffected": 10, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 15, "numAffected": 6, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 70, "numAffected": 9, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 45, "numAffected": 10, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 176, "numAffected": 19, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 60, "numAffected": 16, "numAtRisk": 113}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 10, "numAffected": 8, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 4, "numAffected": 2, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 15, "numAffected": 10, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 8, "numAffected": 5, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 25, "numAffected": 18, "numAtRisk": 113}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 4, "numAffected": 3, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 5, "numAffected": 5, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 6, "numAffected": 5, "numAtRisk": 113}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 62}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 45}, {"groupId": "EG003", "numEvents": 6, "numAffected": 1, "numAtRisk": 51}, {"groupId": "EG004", "numEvents": 5, "numAffected": 5, "numAtRisk": 107}, {"groupId": "EG005", "numEvents": 7, "numAffected": 2, "numAtRisk": 113}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines."}, "pointOfContact": {"title": "Clinical Trials Disclosure", "organization": "Merck Sharp & Dohme LLC", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2018-04-03", "uploadDate": "2020-09-11T10:36", "filename": "Prot_SAP_000.pdf", "size": 2166711}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Argentina", "Australia", "Brazil", "Bulgaria", "Canada", "Chile", "Colombia", "Costa Rica", "Czech Republic", "Denmark", "Georgia", "Greece", "Guatemala", "Honduras", "Hungary", "Israel", "Italy", "Mauritius", "Mexico", "Moldova, Republic of", "Netherlands", "New Zealand", "Panama", "Philippines", "Russian Federation", "Saudi Arabia", "Serbia", "South Africa", "Sri Lanka", "Taiwan", "Ukraine", "United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "relevance": "LOW"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "relevance": "LOW"}, {"id": "M347", "name": "Insulin Glargine", "relevance": "LOW"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}